Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13033162 | 1.00 | PAOX (0.61) | PAOXALDH1A1TSHRKDM4EGAA | |
| SCHEMBL13033093 | 1.00 | PAOX (0.61) | PAOXALDH1A1TSHRKDM4EGAA | |
| SCHEMBL13033102 | 1.00 | PAOX (0.61) | PAOXALDH1A1TSHRKDM4EGAA | |
| SCHEMBL13033097 | 1.00 | PAOX (0.61) | PAOXALDH1A1TSHRKDM4EGAA | |
| SCHEMBL13033090 | 0.98 | PAOX (0.58) | PAOXALDH1A1TSHRKDM4EGAA | |
| SCHEMBL13033088 | 0.94 | PAOX (0.53) | PAOXALDH1A1TSHRKDM4EGAA | |
| SCHEMBL13033089 | 0.90 | PAOX (0.48) | PAOXALDH1A1TSHRKDM4EGAA | |
| SCHEMBL2751863 | 0.88 | ALDH1A1 (0.67) | PAOXALDH1A1TSHRGAALMNA | |
| SCHEMBL8105099 | 0.88 | ALDH1A1 (0.67) | PAOXALDH1A1TSHRGAALMNA | |
| SCHEMBL8464714 | 0.88 | ALDH1A1 (0.67) | PAOXALDH1A1TSHRGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | NMUR1, NMUR2, NMBR | PAOX 1883/4885ALDH1A1 3894/4885TSHR 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.